



Organizer: Doris Zane, PhD, DABT, Executive Director, Nonclinical Safety, Gilead Sciences



Joanne Birkebak, DVM, DABT **Independent Consultant**

Introduction to Nonclinical Safety: Who We Are and What We Do



Toufan Parman, PhD, DABT Senior Director of Nonclinical Safety Evaluation, Sangamo Therapeutics

Genetic Toxicology and Carcinogenicity: What Do We Need and When Do We Need It?



Joel Bercu, PhD, MPH, DABT Executive Director, Gilead **Sciences**

Introduction and Occupational Toxicology



Melisa Masuda-Herrera, MS, DABT Senior Associate Scientist, **Gilead Sciences**

Environmental Toxicology



Dinah Misner, PhD, DABT, **VP, Aligos Therapeutics**

Safety Pharmacology Studies for Discovery and Development of Small Molecules for INDs/NDAs



Ellen McGlinchey, PhD Senior Project Toxicologist (Sr. Research Scientist II), Nonclinical Safety and Pathobiology, Gilead Sciences

Developmental and Reproductive Toxicology (DART) Studies: Small Molecule Designs, Endpoints, and Case Studies



Alejandra Trejo-Martin, MS Senior Associate Scientist. **Gilead Sciences**

Toxicological Assessment of Impurities



Jessica Hawes Oliphant, PhD

Deputy Director, Division of Systems Biology, National Center for Toxicological Research, FDA

Nonclinical Regulatory Perspectives on Small Molecule Drug Development Programs

Major Sponsors







Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices

Organizer: Doris Zane, PhD, DABT, Executive Director, Nonclinical Safety, Gilead Sciences



Time (PST)	Topic	Presenter
8:45 - 9:00 am	PBSS Welcome and Introduction	Shichang Miao, PhD, President, PBSS; Doris Zane, PhD, DABT, Executive Director, Nonclinical Safety, Gilead Sciences
9:00 - 10:00 am	Introduction to Nonclinical Safety: Who We Are and What We Do	Joanne Birkebak, DVM, DABT, Independent Consultant
10:00 - 11:00 am	Safety Pharmacology Studies for Discovery and Development of Small Molecules for INDs/NDAs	Dinah Misner, PhD, DABT, DSP, VP, Aligos Therapeutics
11:00 -11:10 am	Major Sponsor Presentation	Emery Pharma
11:10 -11:30 am	Break and Vendor Show	-
11:30 am -12:30 pm	Genetic Toxicology and Carcinogenicity: What Do We Need and When Do We Need It?	Toufan Parman , PhD, DABT, Senior Director of Nonclinical Safety Evaluation, Sangamo Therapeutics
12:30 - 1:30 pm	Lunch	Sponsor (Pharmaron)
1:30 - 2:30 pm	Developmental and Reproductive Toxicology (DART) Studies: Small Molecule Designs, Endpoints, and Case Studies	Ellen McGlinchey, PhD, Senior Project Toxicologist (Sr. Research Scientist II), Nonclinical Safety and Pathobiology, Gilead Sciences
2:30 - 3:30 pm	Environmental and Occupational Toxicology	Joel Bercu, PhD, MPH, DABT, Executive Director; Melissa Masuda-Herrera, MS, DABT, Senior Associate Scientist; Alejandra Trejo-Martin, MS, Senior Associate Scientist, Environmental and Occupational Toxicology, Gilead Sciences
3:30 - 3:40 pm	Major Sponsor Presentation	WuXi AppTec
3:40 - 4:00 pm	Break and Vendor Show	-
4:00 - 5:00 pm	Nonclinical Regulatory Perspectives on Small Molecule Drug Development Programs	Jessica Hawes Oliphant, PhD, Deputy Director, Division of Systems Biology, National Center for Toxicological Research, FDA
5:00 - 5:30 pm	Panel Discussion	All Speakers
5:30 - 6:30 pm	Happy Hour	Sponsor (Veloxity Labs)





Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: **Nuts, Bolts and Best Practices**

Organizer: Doris Zane, PhD, DABT, Executive Director, Nonclinical Safety, Gilead Sciences



San Francisco Bay Area: Crowne Plaza Foster City; available as webcast to other PBSS chapters

Sponsors



























